Phase 4 N=15 Anterior Pituitary Hormone Replacement in Traumatic Brain Injury
Growth Hormone Deficiency · Traumatic Brain Injury
Primary: Maximum Oxygen Uptake at Baseline. — 29.0 mL/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Phase 3 N=39 LutrePulse Hypogonadotropic Hypogonadism
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
N/A N=43 Peri-Operative Steroid Management in Patients
Pituitary Adenoma · Pituitary Diseases
Primary: Number of Participants With Adrenal Insufficiency — 2; 1 Participants
Phase 2 N=30 An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly
Primary: Percentage of Participants With Growth Hormone (GH) and Insulin-like Growth Factor 1 (IGF-1) Observed Response by Dose Class — 20; 28.6; 14.3; 23.1 percentage of…
Phase 2 N=19 Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Cushing Disease
Primary: Percentage of Responders With Mean Urinary Free Cortisol (UFC) Within Normal Limits — 22.2 percentage of responders
N/A N=10,673 A Prospective Observational Study of Effect of Somatropin on Growth Hormone Deficient Adults
Hypopituitarism · Pituitary Insufficiency · Growth Hormone Deficiency, Adult
Primary: Clinically Significant Adverse Events — 2.58; 3.78; 4.0; 5.3 percentage of participants
Phase 2 N=20 Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
Non-functioning Pituitary Adenoma
Primary: Percentage of Participants With Non-functioning Pituitary Adenomas (NFPA) Who Achieve Tumor Volume Reduction of at Least 20% After 24 Weeks (FAS) — 16.7 percentage of…
Phase 2 N=63 Recombinant Human Growth Hormone During Rehabilitation From Traumatic Brain Injury.
Traumatic Brain Injury
Primary: Functional Outcome 6 Months After Injury, as Measured by the Processing Speed Index — 82.5; 82.5 Processing speed index standardized scor
Phase 3 N=21 Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
Non-functioning Pituitary Adenomas · Prolactinomas
Primary: Tumor Volume Changes for NFPA and Prolactin Level Changes for Prolactinoma — 3.8; 29.35 cmˆ3 — p=<0.05
Phase 4 N=41 Surgical Debulking of Pituitary Adenomas
Pituitary Adenoma
Primary: Percentage of Responders (Primary Medical Treatment in Arm 1, Primary Surgical Treatment in Arm 2) — 6.7; 50 percentage of participants
N/A N=75 Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency
Acromegaly · Growth Hormone Deficiency · Pituitary Disease
Primary: Change in High-sensitivity C-reactive Protein — 2.93; 3.23; -0.36; 1.64 mg/liter
Phase 3 N=11 Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults With Growth Hormone Deficiency
Hypopituitarism
Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI
Phase 2 N=9 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
Phase 3 N=108 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly
Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…
Phase 2 N=33 Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Acromegaly · Pituitary Gigantism
Primary: Total-group Response Rate at Month 3 — 18.2 Percentage of participants
Phase 2 N=27 Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34
Hypoparathyroidism
Primary: Serum Calcium Level — 2; 1.92 mmol/liter
N/A N=367 Programme of Acromegaly Screening in Patients With Associated Somatic Disorders
Acromegaly
Primary: Percentage of Participants Diagnosed With Acromegaly — 5.8; 2.4 percentage of participants
Phase 3 N=68 Bone Properties in Hypoparathyroidism: Effects of PTH
Hypoparathyroidism
Primary: Requirements for Calcium Supplementation — 3.03; 1.66 grams per day of calcium supplementation
Phase 3 N=113 Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants
N/A N=28 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Phase 4 N=20 Testosterone Gel Applied to Women With Pituitary Gland Problems
Panhypopituitarism
Primary: Fatigue Impact Scale — -22.9; 2.2 units on a scale — p=0.08
Phase 2 N=56 Growth Hormone Deficiency in Chronic Heart Failure: A Preliminary Trial
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
N/A N=25 Effects of Short-term Growth Hormone in HIV-infected Patients
HIV Lipodystrophy
Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01
N/A N=21 Hypoglycemia and the Mineralocorticoid Receptor
Hypoglycemia
Primary: Change From Baseline in Cardiovascular Autonomic Function — -16.00; -16.59 ms/mmHg
Phase 2 N=20 Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism
Hypoparathyroidism · Hypocalcemia · Autoimmune Polyendocrine Syndrome Type 1
Primary: Mean Serum Calcium in Children and Young Adults — 2.02; 1.88 mmol/liter — p=0.02
N/A N=230 Drug Use Investigation of Somatropin for GHD-ADULTS.
Dwarfism, Growth Hormone Deficiency
Primary: Number of Participants With Treatment Related Adverse Events. — 29 participants
Phase 3 N=124 Use of NPSP558 in the Treatment of Hypoparathyroidism
Hypoparathyroidism
Primary: The Percentage of Subjects Who Met the Triple Efficacy Endpoint Criteria at Week 24. — 2.5; 54.8 percentage of participants — p=<0.001
N/A N=56 Physiologic Growth Hormone Effects in HIV Lipodystrophy
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Phase 3 N=51 A Open-label Study Investigating the Safety and Tolerability of NPSP558, a Recombinant Human Parathyroid Hormone (rhPTH [1-84]), for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study (RACE)
Hypoparathyroidism
Primary: Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE) — 13; 48 Participants